Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Share-based Compensation (2019 - 2025)

Black Diamond Therapeutics' Share-based Compensation history spans 5 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 13.69% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $6.6 million, down 37.63%, while the annual FY2025 figure was $6.6 million, 37.63% down from the prior year.
  • Share-based Compensation reached $1.4 million in Q4 2025 per BDTX's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.3 million in Q2 2024 to a low of $1.4 million in Q4 2025.
  • Average Share-based Compensation over 3 years is $2.3 million, with a median of $1.7 million recorded in 2025.
  • Peak YoY movement for Share-based Compensation: surged 64.84% in 2021, then tumbled 66.38% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $3.1 million in 2021, then plummeted by 47.12% to $1.6 million in 2024, then decreased by 13.69% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Share-based Compensation are $1.4 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025).